Currently, immunotherapy based on immune checkpoint PD-L1 (programmed death ligand 1) has made remarkable progress in the treatment of advanced lung cancer, accompanying the problem of limited beneficiaries (36). The gene discussed is CD274; the disease is lung carcinoma.